Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is a cholinesterase inhibitor presented as an oral tablet for systemic use. It is used to improve neuromuscular transmission in patients with myasthenia gravis and to aid recovery of bowel function after surgery.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides reliable logistics for global distribution.

Mestinon, a cholinesterase inhibitor, is employed in conditions where enhanced neuromuscular transmission is required. - Myasthenia gravis: improves muscle strength by increasing acetylcholine at the neuromuscular junction. - Postoperative ileus: facilitates return of intestinal motility after abdominal surgery. - Myasthenic crisis: provides symptomatic relief while definitive therapies take effect.

Mestinon may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Abdominal cramps - Increased salivation

Serious or Rare Side Effects: - Cholinergic crisis (muscle weakness, respiratory failure) - Severe bradycardia - Bronchospasm - Allergic reactions (rash, angioedema)

When prescribing Mestinon, clinicians should consider several safety measures to minimize risk. - Dose adjustment in renal impairment: reduce dose based on creatinine clearance. - Monitor for signs of cholinergic excess: muscle twitching, sweating, gastrointestinal symptoms. - Caution in patients with asthma or COPD: risk of bronchospasm. - Avoid concurrent use with other cholinesterase inhibitors: may cause additive effects. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from moisture.

Mestinon can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Neostigmine: additive cholinergic effects may precipitate crisis. - Physostigmine: combined inhibition of acetylcholinesterase can be dangerous. - Beta‑blockers: may mask tachycardia that signals cholinergic excess.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: may potentiate neuromuscular blockade. - Non‑depolarizing muscle relaxants: may enhance muscle weakness. - Anticholinergic drugs (e.g., atropine): may reduce therapeutic effect.